PMID: 7037104Feb 1, 1982Paper

Prostacyclin in prostatic cancer: a better marker than bone scan or serum acid phosphatase?

British Journal of Urology
O KhanG Williams

Abstract

Prostaglandins have been implicated in the development and spread of malignant tumours. Gas chromatography and mass spectrometry (GC-MS) analysis of prostaglandins in benign and malignant prostatic tissue showed that prostacyclin (PGI2), a prostanoid known to induce bone resorption, was the major component. PGI2 is hydrolysed to 6-oxo-PGF1 alpha. Plasma levels of 6-oxo-PGF1 alpha were measured as an index of PGI2 formation in patients with benign and malignant prostatic disease. The mean plasma 6-oxo- level in an age-matched control group was comparable to that of patients with benign prostatic hypertrophy. A significant elevation was found in patients with a TO carcinoma (P less than 0.05). Plasma 6-oxo- levels rise with advancing disease and the concentration varied with the degree of tumour differentiation. Plasma 6-oxo-levels were a more accurate monitor of disease progression than tartrate labile acid phosphatase in patients with M1 carcinoma. Persistently elevated levels were associated with a bad prognosis.

References

Jan 1, 1976·Cancer·M K Schwartz
Dec 1, 1976·Prostaglandins·N WhittakerF F Sun
May 31, 1975·Lancet·A BennettI F Stamford
Nov 1, 1977·The Journal of Urology·K B Cummings, R P Robertson
Mar 1, 1976·Prostaglandins·A BennettI F Stamford
Nov 16, 1968·Lancet·M SandlerE D Williams
Jun 25, 1974·Prostaglandins·B M Jaffe
May 1, 1974·The American Journal of Medicine·L T Yam
Jun 1, 1970·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·K Kovacs, A Somogyi
Dec 1, 1981·The British Journal of Ophthalmology·A SorsbyA G Bennett
Jan 1, 1981·European Journal of Clinical Pharmacology·G G Neri SerneriA Morettini
Feb 1, 1980·British Journal of Obstetrics and Gynaecology·R R SandersW R Jones

❮ Previous
Next ❯

Citations

Jul 1, 1984·Calcified Tissue International·F E Dewhirst
May 24, 2005·Biochemical and Biophysical Research Communications·Matthew WagnerMark Garzotto
Aug 15, 2001·Urology·A KirschenbaumA C Levine
Feb 26, 2000·BJU International·A F Badawi
Aug 1, 2008·Future Lipidology·Kasem Nithipatikom, William B Campbell
Sep 2, 2004·Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine·Zhen ChenYi-Bei He
Aug 1, 1987·Cancer·P Guinan, M Rubenstein
Jun 27, 2006·Nature Reviews. Immunology·Ronald N GermainMichel C Nussenzweig
Dec 1, 1983·The Journal of Urology·J E Pontes

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.